Correlation Between NewAmsterdam Pharma and Relmada Therapeutics

Can any of the company-specific risk be diversified away by investing in both NewAmsterdam Pharma and Relmada Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining NewAmsterdam Pharma and Relmada Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between NewAmsterdam Pharma and Relmada Therapeutics, you can compare the effects of market volatilities on NewAmsterdam Pharma and Relmada Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in NewAmsterdam Pharma with a short position of Relmada Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of NewAmsterdam Pharma and Relmada Therapeutics.

Diversification Opportunities for NewAmsterdam Pharma and Relmada Therapeutics

-0.34

Correlation Coefficient

NewAmsterdam Pharma  Relmada Therapeutics

Very good diversification

The 3 months correlation between NewAmsterdam and Relmada is -0.34. Overlapping area represents the amount of risk that can be diversified away by holding NewAmsterdam Pharma and Relmada Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Relmada Therapeutics and NewAmsterdam Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on NewAmsterdam Pharma are associated (or correlated) with Relmada Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Relmada Therapeutics has no effect on the direction of NewAmsterdam Pharma i.e., NewAmsterdam Pharma and Relmada Therapeutics go up and down completely randomly.

Pair Corralation between NewAmsterdam Pharma and Relmada Therapeutics

Given the investment horizon of 90 days NewAmsterdam Pharma is expected to generate 0.58 times more return on investment than Relmada Therapeutics. However, NewAmsterdam Pharma is 1.72 times less risky than Relmada Therapeutics. It trades about 0.14 of its potential returns per unit of risk. Relmada Therapeutics is currently generating about -0.18 per unit of risk. If you would invest  1,584  in NewAmsterdam Pharma on September 15, 2024 and sell it today you would earn a total of  925.00  from holding NewAmsterdam Pharma or generate 58.4% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

NewAmsterdam Pharma  vs.  Relmada Therapeutics

NewAmsterdam Pharma

Risk-Adjusted Performance

11 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in NewAmsterdam Pharma are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak primary indicators, NewAmsterdam Pharma unveiled solid returns over the last few months and may actually be approaching a breakup point.

Relmada Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Relmada Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's primary indicators remain rather sound which may send shares a bit higher in January 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Pair Trading with NewAmsterdam Pharma and Relmada Therapeutics

The main advantage of trading using opposite NewAmsterdam Pharma and Relmada Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if NewAmsterdam Pharma position performs unexpectedly, Relmada Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Relmada Therapeutics will offset losses from the drop in Relmada Therapeutics' long position.

The idea behind NewAmsterdam Pharma and Relmada Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.